Peptide Receptor Radionuclide Therapy Improves Survival in Patients Who Progress After Resection of Gastroenteropancreatic Neuroendocrine Tumors

Luis C. Borbon,Scott K. Sherman,Patrick J. Breheny,Chandrikha Chandrasekharan,Yusuf Menda,David Bushnell,Andrew M. Bellizzi,P. H. Ear,M. Sue O’Dorisio,Thomas M. O’Dorisio,Joseph S. Dillon,James R. Howe

DOI: https://doi.org/10.1245/s10434-024-16463-7

IF: 4.339

2024-11-08

Annals of Surgical Oncology

Abstract:Peptide receptor radionuclide therapy (PRRT) is an effective treatment for advanced gastroenteropancreatic (GEP) neuroendocrine tumors (NETs). We investigated a 2-decade experience with PRRT to determine whether PRRT confers a survival advantage to patients who progress after surgery versus other therapies.

oncology,surgery